Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 569

1.

The effects of novel antipsychotics on glucose and lipid levels.

Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.

J Clin Psychiatry. 2002 Oct;63(10):856-65.

PMID:
12416594
[PubMed - indexed for MEDLINE]
2.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
[PubMed - indexed for MEDLINE]
3.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
[PubMed - indexed for MEDLINE]
4.
5.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
[PubMed - indexed for MEDLINE]
6.

Novel antipsychotics: comparison of weight gain liabilities.

Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR.

J Clin Psychiatry. 1999 Jun;60(6):358-63.

PMID:
10401912
[PubMed - indexed for MEDLINE]
7.

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Newcomer JW.

CNS Drugs. 2005;19 Suppl 1:1-93. Review.

PMID:
15998156
[PubMed - indexed for MEDLINE]
8.

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.

Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA.

J Clin Psychiatry. 2002 Oct;63(10):920-30.

PMID:
12416602
[PubMed - indexed for MEDLINE]
9.

Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.

McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP.

J Clin Psychiatry. 2005 Sep;66(9):1161-8.

PMID:
16187775
[PubMed - indexed for MEDLINE]
10.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
[PubMed - indexed for MEDLINE]
11.

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS.

Psychopharmacology (Berl). 2006 Jul;186(4):572-8. Epub 2006 Apr 7.

PMID:
16601995
[PubMed - indexed for MEDLINE]
12.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
[PubMed - indexed for MEDLINE]
13.

Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.

Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT.

J Clin Psychiatry. 2001 Sep;62(9):694-700.

PMID:
11681765
[PubMed - indexed for MEDLINE]
14.

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.

Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR.

J Clin Psychiatry. 2003 Sep;64(9):1133-4. No abstract available.

PMID:
14628994
[PubMed - indexed for MEDLINE]
15.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
[PubMed - indexed for MEDLINE]
16.

Glucose intolerance with atypical antipsychotics.

Hedenmalm K, Hägg S, Ståhl M, Mortimer O, Spigset O.

Drug Saf. 2002;25(15):1107-16.

PMID:
12452735
[PubMed - indexed for MEDLINE]
17.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
[PubMed - indexed for MEDLINE]
18.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Apr;62(4):231-8.

PMID:
11379836
[PubMed - indexed for MEDLINE]
19.

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.

Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B.

Schizophr Res. 2009 Feb;107(2-3):115-21. doi: 10.1016/j.schres.2008.09.028. Epub 2008 Nov 6.

PMID:
18993033
[PubMed - indexed for MEDLINE]
20.

Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents.

Melkersson KI, Hulting AL.

Psychopharmacology (Berl). 2001 Mar 1;154(2):205-12.

PMID:
11314683
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk